



NEONATAL MEDICATION PROTOCOLS

FLUCYTOSINE
 Created by: NCCU
 Date for review: Aug 2016

NCCU Clinical Guidelines
 KEMH/PMH
 Perth, Western Australia

DRUG:	FLUCYTOSINE
PRESENTATION:	Infusion solution: 2.5 g/250 mL Unit dose syringes: 10 mg/mL (Prepared in Pharmacy). Oral Solution: 10mg/mL (Prepared in Pharmacy).
ACTION & INDICATION:	Antifungal agent for systemic fungal infections. Should always be used in combination with another appropriate antifungal agent.
DOSE:	Usual dose: 25-37.5 mg/kg/dose 6 hourly Severe infection: 50 mg/kg/dose 6 hourly Acute infections: 2 - 4 weeks therapy Subacute/chronic infections: prolonged therapy
ADMINISTRATION:	Intravenous: Infuse over 30 minutes via syringe pump Oral: May be given at any time with regard to feeds.
ADVERSE EFFECTS:	Bone marrow toxicity Hepatotoxicity
COMMENTS:	Increase interval between doses in renal impairment. Must be used in combination with another antifungal agent Store intravenous preparations between 15 and 25 C Cytotoxic handling and disposal procedures should be followed
DRUG MONITORING:	Sampling time: Pre and post levels to be taken at the THIRD dose (so as to ensure therapeutic levels) and weekly thereafter. Trough level: Immediately prior to dose. Peak level: IV: 30 minutes after completion of infusion. Oral: 3 hours post dose Trough: 25 - 40 mg/L Peak: 60 – 80 mg/L
REFERENCES:	Neofax 2012
DATE:	August 2013